summary of the Clinical Trial Protocol (Descartes-08 for Myasthenia Gravis)
This text details the protocol for a clinical trial (MG-001,Part 3) investigating the efficacy and safety of Descartes-08,an autologous cell therapy,for the treatment of generalized Myasthenia Gravis (gMG). Here’s a breakdown of the key aspects:
1. Study Design & Phases:
* Phase: Part 3 of a larger MG-001 study.
* Randomization: 1:1 randomization to either Descartes-08 or placebo.
* Blinding: Double-blinded through month 3, with an open-label crossover option for placebo participants.
* Follow-up: All participants followed for 12 months.
* Amendments: The protocol underwent several amendments to refine enrollment, primary endpoint definition, and statistical analysis.
2. Participants:
* Inclusion Criteria:
* Adults (≥18 years) with gMG (MGFA Class III/IV initially, then II-IV).
* Currently on immunosuppressive medications.
* Stable corticosteroid dose (≤40mg prednisone equivalent) for at least 4 weeks.
* Seropositive (specific antibody titer above normal) or Seronegative (response to cholinesterase inhibitors & abnormal nerve stimulation).
* MG-ADL score of ≥6.
* Willingness to participate and provide informed consent.
* Effective contraception for women of reproductive potential.
* Exclusion Criteria:
* Notable uncontrolled medical conditions.
* Recent immunoglobulin/plasma exchange or certain immunosuppressant treatments (rituximab, ocrelizumab, calcineurin inhibitors, FcRn antagonists, eculizumab).
* Pregnancy or inadequate contraception.
* Significant lab abnormalities (blood counts, liver function, kidney function).
* History of primary immunodeficiency, organ transplant, or active infections.
* Recent malignancy or vaccinations.
* Uncontrolled cardiac/pulmonary disease or psychiatric illness.
3. Treatment & Concomitant Medications:
* Intervention: Descartes-08 (autologous cell therapy) or placebo.
* Concomitant Medications: Allowed, including pyridostigmine, corticosteroids (stable dose ≤40mg), azathioprine, mycophenolate mofetil, and complement inhibitors. Corticosteroid doses coudl be tapered after month 6, but not increased.
4. Randomization & Blinding:
* Centralized Randomization: Using a permuted-block scheme.
* Blinding maintenance: Infusion bags where covered to maintain blinding.
* Unequal Allocation: The study acknowledges potential for unequal group sizes due to enrollment issues.
5.Endpoints:
* Primary Endpoint: Proportion of participants achieving a ≥5-point reduction in the Myasthenia Gravis Composite (MGC) score at month 3.
In essence, this trial aims to evaluate whether Descartes-08 can improve the symptoms of gMG, as measured by the MGC score, in patients who are already receiving standard immunosuppressive treatment. The study is rigorously designed with blinding and a defined set of inclusion/exclusion criteria to ensure reliable results.
Worth a look